Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Financings

DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants

By The Northwire Desk — AI Analysis Mar 05, 2026 · 15:45 ADK · 0.31 Diagnos Inc.
ADK · Price

Executive Summary

  • Diagnos Inc. announced amendments to its $510,000 unsecured convertible debentures, extending maturity to March 1 2027 and lowering the conversion price from $0.38 to $0.32 while maintaining a 10% annual interest rate.
  • The company also extended the expiry of 8,333,333 stock warrants (exercise price $0.40) from March 20 2026 to September 5 2026.
  • Both amendments remain subject to TSX Venture Exchange approval and will be formalized through execution of documentation.

Key Details

  • Debenture Amendment
  • Original aggregate amount: $510,000 unsecured convertible debentures.
  • Maturity date extended from March 1 2026 to March 1 2027.
  • Conversion price reduced from $0.38 per share to $0.32 per share.
  • Annual interest rate remains at 10% for the extended period (Mar 1 2026 – Mar 1 2027).
  • All other terms unchanged.
  • Related Party Disclosure
  • Insider André Larente holds 2 debentures with a nominal aggregate value of $20,000.
  • Amendment exempt from MI 61‑101 valuation and minority approval requirements (fair market value < 25% of market cap).
  • Warrant Extension
  • 8,333,333 stock warrants issued in the September 20 2024 private placement.
  • Original expiry: March 20 2026; extended to September 5 2026.
  • Exercise price unchanged at $0.40 per common share.
  • Regulatory Conditions
  • Amendments subject to acceptance by the TSX Venture Exchange and execution of formal documentation.
  • Company will issue a follow‑up press release only if the Exchange rejects any amendment.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Diagnos Inc.

Jun 18, 2026 · 12:00

Cash-preserving debt settlement underscores ongoing liquidity constraints ahead of critical CARA regulatory milestones.

Financings Jun 16, 2026 · 09:15

Pre-revenue medical AI developer navigating regulatory hurdles while burning through cash reserves.

Regulatory Jun 05, 2026 · 10:00

DIAGNOS Inc. Awaits Health Canada Catalyst as Cash Runway Narrows Ahead of Dilutive Financing

Regulatory Apr 08, 2026 · 12:14

Regulatory timeline update keeps CARA on track, no surprise for investors

Production / Operations Mar 05, 2026 · 18:26

Diagnos to amend convertible debenture, warrant terms

Financings Feb 04, 2026 · 20:07

Diagnos expects to receive $1M in federal investments

Other